Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q2 2015 · 10-Q
Revenue—
Net Income-$3.37M-$3.37MN/M vs Q2 2014 EPS Diluted-$0.07-$0.07N/M vs Q2 2014 Operating Income-$3,387,000N/M Operating Cash Flowderived-$1,948,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,948,000N/M ended Jun 30, 2015 · filed Jul 23, 2015 · 23 d after period end